Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs January 21, 2025
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology January 15, 2025
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma January 15, 2025
Avenzo Therapeutics and DualityBio Announce Exclusive Global License for EGFR/HER3 ADC January 15, 2025
BrainChild Bio, Inc. to clinically advance BCB-276, an autologous B7-H3 targeting CAR T-cell therapy for incurable pediatric brain tumors January 15, 2025
Biocytogen and Acepodia to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors January 15, 2025
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform January 15, 2025
Astraveus Announces World First End-to-End Production of CAR-T Cells Using Microfluidic Technology January 15, 2025
NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products January 15, 2025
Asher Bio Announces Clinical Trial Collaboration & Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in SCLC Patients January 15, 2025
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale January 15, 2025
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 ADC January 7, 2025
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement January 7, 2025
BeiGene to acquire global development, manufacturing, and commercialization rights for an ADC from DualityBio January 7, 2025
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849 Targeting SCLC and NET Solid Tumors December 31, 2024
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia December 31, 2024
Inceptor Bio and GRIT Bio Announce Strategic Partnership to Advance IB-T101, a Next-Generation Solid Tumor CAR-T Utilizing the OUTLAST™ Platform December 26, 2024
Marker Therapeutics Awarded $9.5 Million Grant from the CPRIT to Support the Investigation of MT-601 in Patients with Pancreatic Cancer December 26, 2024
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics December 26, 2024
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement December 26, 2024
Merck Closes Exclusive Global License Agreement for Anti-PD-1/VEGF Bispecific Antibody LM-299 December 26, 2024
